Compass Therapeutics, Inc.
NASDAQ:CMPX
Overview | Financials
Company Name | Compass Therapeutics, Inc. |
Symbol | CMPX |
Currency | USD |
Price | 1.5 |
Market Cap | 206,383,500 |
Dividend Yield | 0% |
52-week-range | 0.765 - 2.34 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Thomas J. Schuetz M.D., Ph.D. |
Website | https://www.compasstherapeutics.com |
An error occurred while fetching data.
About Compass Therapeutics, Inc.
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD